Anti-SARS-CoV-2 Therapeutic Human Monoclonal Antibodies from COVID-19 Recovered Patient Sera

To combat the raging COVID-19 epidemic, Creative Biolabs, as one of industry-leading CROs, has integrated our advanced technical resources to help researchers develop COVID-19 drugs faster and better.

Globally Spread SARS-CoV-2

Anti-SARS-CoV-2 Therapeutic Human Monoclonal Antibodies from COVID-19 Recovered Patient Sera

With the spread of new coronavirus SARS-CoV-2 in the world, the cumulative number of COVID-19 cases in the United States has exceeded 120,000, and the number of new cases has exceeded 20,000 in a single day. It has become the epicenter of a global pandemic. For new human pathogens such as SARS-CoV-2, special drugs or vaccines cannot be expected in a short time. The outbreak of the COVID-19 epidemic in many countries has faced great challenges to global public health security. Since there is currently no special antiviral drug for COVID-19 treatment. COVID-19 recovered patient sera is one of the potential therapies currently under investigation.

Therapeutic Potential of COVID-19 Recovered Patient Sera

When people recover from viral diseases, neutralizing antibodies are produced in the blood. Such antibodies can be used to prevent infections in contacts, and may also be used to treat sick people, which is called "passive antibody therapy". On April 6th, a research team revealed in a PNAS paper that in 10 patients with severe adult COVID-19, as maximum supportive care and supplementary treatment of antiviral drugs, a single dose (200 mL) of COVID-19 recovered patient plasma is well tolerated, and can significantly increase or maintain the neutralizing antibody at a high level, which in turn leads to the disappearance of viremia within 7 days. At the same time, the clinical symptoms and related indicators of severe COVID-19 patients receiving plasma therapy improved rapidly within 3 days. During the therapy period, plasma oxygen saturation increased within 3 days, lymphocyte count increased (0.65×109/L vs 0.76×109/L), and C-reactive protein level decreased (55.98 mg/L vs 18.13 mg/L). Radiological examination also showed that in the 7 days of treatment, the lung lesions of the patient showed different degrees of absorption. The results demonstrated that the plasma in the recovery phase has the potential to improve the clinical outcome of severe COVID-19 patients by neutralizing viremia.

Screening of Therapeutic Human Monoclonal Antibodies from COVID-19 Recovered Patient Sera

One of the main challenges and concerns of plasma therapy is to ensure the prevention of transfusion-transmitted infections (TTI). Due to the globalization of the epidemic, the regulatory system may require more testing to improve the safety of blood transfusions. For example, a study in the United Kingdom suggested that because blood donors were not screened for hepatitis E virus (HEV), infections were common among the British population and blood donors. In this case, the infusion of rehabilitation plasma may cause long-term or persistent infections. To address this limitation, Creative Biolabs now provides therapeutic human monoclonal antibody screening services from COVID-19 recovered patient sera via its advantage in antibody discovery.

Highlight Platform

If you are interested in our service, please feel free to contact us.

Reference

  1. Kai Duan, Bende Liu, et al. (2020). “Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.” Proc Natl Acad Sci U S A. Apr 28; 117(17): 9490–9496.
For Research Use Only. We do not provide services or products directly for patients.


Online Inquiry For Research Use Only. We do not provide services or products directly for patients.
  • Verification code
    Click image to refresh the verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Inquiry

Top
Inquiry Basket